Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Picrorhiza kurroa** (also known as "Kutki") is a perennial herb native to the Himalayan region, valued in Ayurvedic medicine for its bitter rhizomes used primarily as a hepatoprotective agent. Its key active constituents, kutkin (a mixture of picroside I, picroside II, kutkoside, and other iridoid glycosides), exhibit liver-protective effects by reducing elevated liver enzymes (SGOT, SGPT), promoting hepatic regeneration, and protecting against toxins like acetaminophen, galactosamine, and viruses such as hepatitis B and C. It demonstrates anti-inflammatory activity via NF-κB modulation, antioxidant properties, immunomodulation by enhancing cytokine production (IFN-γ, IL-4), antibacterial effects against Gram-positive and Gram-negative bacteria, anticancer cytotoxicity in cell lines (breast, liver, prostate), antidiabetic effects by lowering blood glucose and improving GLUT-4 translocation, and additional benefits in asthma, vitiligo, and skin disorders. Clinical trials support its use in acute viral hepatitis, NAFLD, NASH, and vitiligo, typically at 300-500 mg doses of rhizome powder 2-3 times daily, with a favorable safety profile from traditional use though mild GI side effects like diarrhea can occur.[1][2][3][4][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on picrorhiza kurroa.